Category Pharmaceutical Industry

North Dakota to Receive Nearly $3 Million in Whistleblower Lawsuit [Legal Monitor Worldwide]

Dec31

The state of North Dakota will be receiving nearly $3 million for its state Medicaid program as part of a whistleblower settlement between the federal government and a major pharmaceutical company.A Tuesday release from the North Dakota Department of Human Services announced that the state Medicaid program will receive about $2.99 million. The money comes […]

IGI Laboratories, Inc. Completes Its Sixth ANDA Filing For 2013 Under Joint Drug Development And Commercialization Agreement

Dec31

BUENA, N.J., Dec. 31, 2013 /PRNewswire/ IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it executed a license, development, supply and marketing agreement with a large multi-national pharmaceutical company. In accordance with the confidentiality agreement in place, the name of the company remains undisclosed. The agreement designates […]

Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack

Dec30

By a News Reporter-Staff News Editor at Clinical Trials Week Capricor Therapeutics, Inc. (OTCBB: NLTXD) announced that it has received notification from the National Heart Lung and Blood Institute (NHLBI) Gene and Cell Therapy (GST) Data Safety Monitoring Board (DSMB) that the 14-patient Phase I portion of the Company’s ALLSTAR Phase I/II clinical trial has […]

Idera Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report (Dec. 13, 2013)

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Idera Pharmaceuticals, Inc. (Form 8-K) was posted on December 13, 2013.The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).There was one […]

Nps Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Dec. 16, 2013)

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Nps Pharmaceuticals Inc. (Form 4) was posted on December 16, 2013.The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).There was one […]

Teva to Report Fourth Quarter 2013 Financial Results on February 6, 2014

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that it will release its fourth quarter 2013 financial results on Thursday, February 6, 2014 at 7:00 a.m. ET (see also Teva Pharmaceutical Industries Ltd.).Teva will host a conference call and live webcast on the same day, at 8:00 […]

Enzon Pharmaceuticals Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Dec. 13, 2013)

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Enzon Pharmaceuticals Inc. (Form 3) was posted on December 13, 2013.The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).There was one […]

Adamis Pharmaceuticals Corp. Files SEC Form 424B4, Prospectus [Rule 424(B)(4)] (Dec. 16, 2013)

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Adamis Pharmaceuticals Corp. (Form 424B4) was posted on December 16, 2013.The SIC code for this company is 2834, Pharmaceutical Preparations.There were 2 documents filed with […]

InSite Vision Highlights Positive Confirmatory Phase 3 Results for BromSite [Professional Services Close

Dec30

InSite Vision announced top-line results from its recently completed confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.According to a release, BromSite combines a low dose (0.075 percent) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s DuraSite drug delivery technology.In addition, InSite Vision noted:The […]

Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Dec. 13, 2013)

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Ligand Pharmaceuticals Inc. (Form 4) was posted on December 13, 2013.The SIC code for this company is 2834, Pharmaceutical Preparations.There was one document filed with […]